<DOC>
	<DOCNO>NCT01936649</DOCNO>
	<brief_summary>The aim study assess reproducibility quantitative measurement myocardial uptake Iobenguane I 123 planar single photon emission compute tomography ( SPECT ) image follow intravenous ( i.v . ) administration AdreView . Efficacy assess base upon absolute difference quantitative analysis image data 2 scan perform 5 14 day apart .</brief_summary>
	<brief_title>Open-label , Test-retest Study Assessing Reproducibility Quantitative Measurements Myocardial Uptake AdreView .</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>The participant originally diagnose New York Heart Association ( NYHA ) Class IIIII HF due ischemic heart disease least 3 month due nonischemic cardiomyopathy least 6 month enrollment study . The participant Left Ventricular ( LV ) dysfunction Left Ventricular Ejection Fraction ( LVEF ) less equal 35 % measure appropriate method ( e.g. , radionuclide contrast ventriculography , electrocardiogram [ ECG ] gate SPECT myocardial perfusion image [ MPI ] , magnetic resonance [ MR ] imaging , compute tomography [ CT ] echocardiography ) within 6 month enrollment study document participant 's medical record . The participant history compliance prescribe heart failure ( HF ) medication take HF guidelinesbased medication study entry include minimum betablocker either angiotensin convert enzyme inhibitor angiotensin receptor antagonist unless document intolerant class medication . The participant stable medical regimen minimum 3 month , hospitalization change HF medication HF symptom . Participants must clinically stable least 7 day enrol study ( e.g. , experience continue chest pain hemodynamic instability ) . The participant previously receive 123 ImIBG 131 ImIBG . The participant know suspected hypersensitivity/allergy iodine , Iobenguane excipients AdreView . The participant heart transplant time prior enrollment . The participant LVEF &gt; 35 % measure appropriate method ( e.g. , radionuclide contrast ventriculography , ECGgated SPECT MPI , MR , CT , echocardiography ) within 30 day prior enrollment study . The participant receive defibrillation either external via implantable cardioverter defibrillator ( ICD ) , antitachycardia pacing , cardioversion treat arrhythmic event previous 90 day . The participant cardiac revascularization , insertion ICD , acute myocardial infarction within 30 day study entry . The participant use follow medication : Amitriptyline derivative , imipramine derivative , antidepressant inhibit norepinephrine transporter , antihypertensives deplete norepinephrine store inhibit reuptake , sympathomimetic amine cocaine . The participant either NYHA Class I NYHA Class IV HF time study entry . The participant renal insufficiency ( creatinine &gt; 3 mg/dl ) . The participant participate clinical trial involve IMP device within 30 day prior first administration AdreView™ . In investigator 's opinion , participant 's medical history include either extensive lifetime exposure ionize radiation ( medical , occupational , ) document total radiation dose &gt; 50 mSv previous 5 year . The participant experience HF hospitalization , increase HF symptom without hospitalization , change increase HF medication previous 3 month . The participant serious noncardiac medical condition associate significant elevation plasma catecholamine , include pheochromocytoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Nuclear image</keyword>
	<keyword>Radiopharmaceutical</keyword>
	<keyword>Iobenguane</keyword>
	<keyword>I-123</keyword>
	<keyword>reproducibility</keyword>
	<keyword>Quantitative measurement</keyword>
	<keyword>myocardial uptake</keyword>
	<keyword>SPECT imaging</keyword>
	<keyword>planar imaging</keyword>
	<keyword>AdreView™</keyword>
</DOC>